IGF2BP2 and cystic fibrosis: Mechanistically, in-vivo and in-vitro evidence indicated that Airn could protect IMP2 from degradation and restore its recognition of m6A-modified p53 mRNA, along with promoting its stabilization, thus ultimately preventing high-glucose-induced CF activation.